U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H17ClN2O
Molecular Weight 288.772
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TETRAZEPAM

SMILES

CN1C2=CC=C(Cl)C=C2C(=NCC1=O)C3=CCCCC3

InChI

InChIKey=IQWYAQCHYZHJOS-UHFFFAOYSA-N
InChI=1S/C16H17ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h5,7-9H,2-4,6,10H2,1H3

HIDE SMILES / InChI

Molecular Formula C16H17ClN2O
Molecular Weight 288.772
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Tetrazepam was the most widely prescribed muscle relaxant in Germany. After a series of studies, which have shown, that tetrazepam caused cutaneous adverse effects and toxic epidermal necrolysis, the drug was withdrawn from the market.

Approval Year

PubMed

PubMed

TitleDatePubMed
An updated overview of clinical guidelines for the management of non-specific low back pain in primary care.
2010-12
Analysis of six benzodiazepines in vitreous humor by high-performance liquid chromatography-photodiode-array detection.
2010-11
[Multimodal treatment of chronic unspecific low back pain].
2010-09-14
Solubilization of poorly water-soluble drugs by mixed micelles based on hydrogenated phosphatidylcholine.
2010-08-16
Development and validation of an EI-GC-MS method for the determination of benzodiazepine drugs and their metabolites in blood: applications in clinical and forensic toxicology.
2010-08-01
Assessment of abuse potential of benzodiazepines from a prescription database using 'doctor shopping' as an indicator.
2010-07
The impact of perfectionism and anxiety traits on action monitoring in major depressive disorder.
2010-07
Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings.
2010-06
Occupational allergic contact dermatitis from tetrazepam in nurses.
2010-05
Experimental design for optimization of microwave-assisted extraction of benzodiazepines in human plasma.
2010-05
Benzodiazepines medazepam and midazolam are activators of pregnane X receptor and weak inducers of CYP3A4: investigation in primary cultures of human hepatocytes and hepatocarcinoma cell lines.
2010-03-15
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009-10-02
Occupational airborne contact allergy to tetrazepam in a geriatric nurse.
2009-10
No cross-reactions between tetrazepam and other benzodiazepines: a possible chemical explanation.
2009-07
Lumbar spondylosis: clinical presentation and treatment approaches.
2009-06
Metabolic studies of tetrazepam based on electrochemical simulation in comparison to in vivo and in vitro methods.
2009-04-10
Unraveling the metabolic transformation of tetrazepam to diazepam with mass spectrometric methods.
2008-12
[Current differential diagnosis of hypereosinophilic syndrome].
2008-08-01
Probable drug rash with eosinophilia and systemic symptoms syndrome related to tetrazepam.
2008-07
Patch testing in non-immediate drug eruptions.
2008-06-15
Systemic dermatitis due to tetrazepam.
2008
Acute generalized exanthematous pustulosis due to tetrazepam.
2008
Detection of diazepam in urine, hair and preserved oral fluid samples with LC-MS-MS after single and repeated administration of Myolastan and Valium.
2007-08
[Comparative study on Chinese medicine and western medicine for treatment of prolapse of lumbar intervertebral disc].
2007-05
Medicolegal aspects of tetrazepam metabolism.
2007-05
Development of in situ ion selective sensors for dissolution.
2007-01-02
Erythema multiforme to tetrazepam.
2007
Toxic epidermal necrolysis caused by tetrazepam.
2006-10
Toxic epidermal necrolysis caused by tetrazepam.
2006-04
Determination of ibuprofen and tetrazepam in human urine by micellar electrokinetic capillary chromatography.
2006-01
Screening method for benzodiazepines and hypnotics in hair at pg/mg level by liquid chromatography-mass spectrometry/mass spectrometry.
2005-10-15
Windows of detection of tetrazepam in urine, oral fluid, beard, and hair, with a special focus on drug-facilitated crimes.
2005-10
Screening and confirmatory method for benzodiazepines and hypnotics in oral fluid by LC-MS/MS.
2005-06-10
Medicinal and injection therapies for mechanical neck disorders.
2005-04-18
Occupational airborne contact dermatitis from sporadic exposure to tetrazepam during machine maintenance.
2005-03
[Drug Safety. Preventing medication errors].
2004-09-17
Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization.
2004-08
Sex-dependent modulation of treatment response.
2004-03
Possible mechanism(s) for relaxant effect of aqueous and macerated extracts from Nigella sativa on tracheal chains of guinea pig.
2004-02-25
Occupational airborne contact allergy to tetrazepam.
2003-11
Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome p-450 CYP2C9.
2003-07
[Medical treatment of spasticity].
2003-05
[Determination of benzodiazepine derivatives mixture by high performance liquid chromatography].
2003
Direct injection micellar liquid chromatographic determination of benzodiazepines in serum.
2002-11-25
Formulating and stability of benzodiazepines in a new lipid emulsion formulation.
2002-11
Tetrazepam drug sensitivity -- usefulness of the patch test.
2002-09
[Analysis of benzodiazepine derivative mixture by gas-liquid chromatography].
2002
Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions.
2001-12
Development of a novel parenteral formulation for tetrazepam using a lipid emulsion.
2001-11
Adverse reaction to tetrazepam.
2001
Patents

Sample Use Guides

Tetrazepam was given orally as a single dose of 50 mg and repeated administration for 5 consecutive days of 50 mg at 12-h intervals, in tablet form
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:58:19 GMT 2025
Edited
by admin
on Mon Mar 31 17:58:19 GMT 2025
Record UNII
FO92091VP8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TETRAZEPAM
EP   INN   MART.   MI   WHO-DD  
INN  
Official Name English
MYOLASTAN
Preferred Name English
Tetrazepam [WHO-DD]
Common Name English
CB 4261
Code English
tetrazepam [INN]
Common Name English
TETRAZEPAM [EP MONOGRAPH]
Common Name English
TETRAZEPAM [MART.]
Common Name English
CB-4261
Code English
TETRAZEPAM [MI]
Common Name English
Classification Tree Code System Code
WHO-VATC QM03BX07
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
WHO-ATC M03BX07
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
DEA NO. 2886
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
NCI_THESAURUS C1012
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
Code System Code Type Description
INN
2182
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY
SMS_ID
100000082738
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY
DRUG CENTRAL
2614
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY
ChEMBL
CHEMBL2105527
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY
MERCK INDEX
m10661
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY Merck Index
FDA UNII
FO92091VP8
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY
PUBCHEM
25215
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY
DRUG BANK
DB13324
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY
WIKIPEDIA
TETRAZEPAM
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY
EVMPD
SUB10946MIG
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY
CAS
10379-14-3
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY
NCI_THESAURUS
C74282
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY
EPA CompTox
DTXSID00146058
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY
ECHA (EC/EINECS)
233-837-7
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY
RXCUI
37985
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY RxNorm
MESH
C005245
Created by admin on Mon Mar 31 17:58:19 GMT 2025 , Edited by admin on Mon Mar 31 17:58:19 GMT 2025
PRIMARY
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY